(Press-News.org) (Embargoed) CHAPEL HILL, N.C. – Results of a clinical trial that began in 2001 show that a gene therapy cocktail conveyed into the brain by a molecular special delivery vehicle may help extend the lives of children with Canavan disease, a rare and fatal neurodegenerative disorder.
A report of the trial appears in the Dec. 19, 2012 online edition of the journal Science Translational Medicine.
The form of gene therapy was created and developed at the University of North Carolina School of Medicine. The work was spearheaded by R. Jude Samulski, PhD, a study senior author, professor of pharmacology and director of UNC's Gene Therapy Center. The treatment uses a virus (adeno-associated virus, or AAV) as a "viral vector" meticulously tailored to enter the brain and safely switch good genes for bad.
"This was the first AAV-based gene therapy produced by a U.S. academic institution to be approved for neurological use by the FDA," Samulski said. "It's also the first vector produced by the university's Gene Therapy Center Vector Core facility to go into patients."
Children with Canavan disease have mutations in the ASPA gene that normally codes for an enzyme that helps the brain degrade N-acetyl-aspartate (NAA). The unregulated buildup of NAA is toxic to the brain's gray matter, the protective myelin sheath surrounding nerve cells. As the myelin deteriorates and neurons becoming unable to communicate, the child's head size increases (macrocephaly), there are movement problems such as an inability to crawl, seizures occur, vision becomes impaired, and the children often die within three years of age. Fewer than 1,000 children in the U.S. have the disorder.
Samulski arrived at UNC in 1993 to establish the UNC Gene Therapy Center and has long pioneered methodologies for using viruses to deliver genes effectively and safely to various targets in the body, including the brain, lungs, liver, heart, and muscle. As a graduate student at the University of Florida in the early 1980s, his thesis project was understanding and developing AAV as a vector for delivering therapeutic genes which has help launch this new field of molecular medicine. This work eventually led to development of AAV type 2, which has been used for gene therapy vector trials in cystic fibrosis, hemophilia, Parkinson's diseases, retinal disorders, and in several other settings, including the first gene therapy clinical trial for muscular dystrophy in the U.S developed by Dr. Samulski and his first graduate student, Dr. Xiao Xiao, professor in the UNC Eshelman School of Pharmacy.
In this Canavan disease phase 1/2 safety study, 13 children were treated at the Cell and Gene Therapy Center at the University of Medicine and Dentistry of New Jersey (UMDNJ) in Stratford, N.J. Principal Investigator and first author of the study is Paola Leone, PhD, associate professor of cell biology at UMDNJ. The children were treated in 2001, 2003 and 2005, corresponding to AAV vector production runs. Their ages at the time of treatment ranged from four to 83 months.
Working with Samulski's UNC lab colleagues, Leone's neurosurgical team used MRI imaging to guide them to the proper location and depth in the lateral ventricle of the brain for inserting six very thin catheters via small holes drilled in the skull.
The team then pumped in a solution carrying the vector package containing the replacement ASPA gene. This amounted to about 900 billion genomic particles of replacement gene held by the AAV vector – roughly the size of a quarter – that were pumped into each of the six catheter sites. The catheters were then removed.
Following the treatments, the patients went home with their families and were tracked with behavioral tasks and brain imaging studies. The investigators found that the gene therapy was safe and has led to a decrease in NAA in the brain, together with decreased seizure frequency and "clinical stabilization," the greatest observed in youngest patients, those treated before 2 years of age. These include improvements in attention, sleep, and greater degree of movement improvements when lying down and rolling.
"As the trial continued, the FDA let us go to younger and younger patients," Samulski said. "We were successful in being able to treat a 3-months-old infant who was diagnosed in utero … and that child is alive today and is the youngest person who has ever been treated with gene therapy."
The UNC scientist views the study a definite success from the safety perspective. "The genetic information put into the brains of individuals has not caused adverse effects, toxicity, or cancer. It also has great potential efficacy for treating other degenerative neurological disorders, including Parkinson's and Alzheimer's diseases."
INFORMATION:
Co-authors along with Samulski at UNC and Leone at UMDNJ were from six academic and clinical sites the U.S. and New Zealand: Children's Hospital of Philadelphia, New York University School of Medicine, Cooper Neurological Institute in Camden, N.J., the University of Minnesota Medical School in Minneapolis, the University of Auckland in Auckland, New Zealand, Ohio State University in Columbus, Ohio, and from Asklepios Biopharmaceuticals in Chapel Hill, N.C.
Funds in support for the research came from the National Institute of Neurological Disorders and Stroke (NINDS), Canavan Research Foundation, Jacob's Cure Foundation, and the National Endowment for Alzheimer's Research.
Gene therapy cocktail shows promise in long-term clinical trial for rare fatal brain disorder
2012-12-20
[Attachments] See images for this press release:
ELSE PRESS RELEASES FROM THIS DATE:
New study sheds light on dinosaur size
2012-12-20
Dinosaurs were not only the largest animals to roam the Earth - they
also had a greater number of larger species compared to all other back-boned animals - scientists suggest in a new paper published in the journal PLOS ONE today.
The researchers, from Queen Mary, University of London, compared the size of the femur bone of 329 different dinosaur species from fossil records. The length and weight of the femur bone is a recognised method in palaeontology for estimating a dinosaur's body mass.
They found that dinosaurs follow the opposite pattern of body size distribution ...
Stem cell research shows ALS may be treatable
2012-12-20
Boston – Results from eleven independent ALS (Lou Gehrig's Disease) research studies are giving hope to the ALS community – showing for the first time that the disease may be treatable by targeting new mechanisms revealed by neural stem cell-based studies. A decade of research conducted at multiple institutions, shows that when neural stem cells were transplanted into multi-levels of the spinal cord of a mouse model with familial ALS, disease onset and progression slowed, motor and breathing function improved and treated mice survived three to four times longer than untreated ...
Impaired melatonin secretion may play a role in premenstrual syndrome
2012-12-20
A new study by Douglas Mental Health University Institute researchers shows altered body rhythms of the hormone melatonin in Premenstrual dysphoric disorder (PMDD) women with insomnia. This finding may help explain some of the sleep disruptions experienced by women with PMDD, also known as premenstrual syndrome. PMDD is a mood disorder which appears in the week preceding menses, and affects about 3-8% of women. PMDD sufferers can experience depression, tension, and irritability of sufficient intensity to interfere with daily activities and relationships. Disturbed sleep ...
Genomic frontier: The unexplored animal kingdom
2012-12-20
HOUSTON -- (Dec. 19, 2012) -- A new report in the journal Nature unveils three of the first genomes from a vast, understudied swath of the animal kingdom that includes as many as one-quarter of Earth's marine species. By publishing the genomes of a leech, an ocean-dwelling worm and a kind of sea snail creature called a limpet, scientists from Rice University, the University of California-Berkeley and the Department of Energy's Joint Genome Institute (JGI) have more than doubled the number of genomes from a diverse group of animals called lophotrochozoans (pronounced: LOH-foh-troh-coh-zoh-uhns).
Lophotrochozoans ...
Inside the head of a dinosaur
2012-12-20
An international team of scientists, including PhD student Stephan Lautenschlager and Dr Emily Rayfield of the University of Bristol, found that the senses of smell, hearing and balance were well developed in therizinosaurs and might have affected or benefited from an enlarged forebrain. These findings came as a surprise to the researchers as exceptional sensory abilities would be expected from predatory and not necessarily from plant-eating animals.
Therizinosaurs are an unusual group of theropod dinosaurs which lived between 145 and 66 million years ago. Members ...
Alzheimer's Disease: Inflammation as a new therapeutic approach
2012-12-20
The number of Alzheimer's patients will continue to dramatically increase in the next several decades. Various teams of researchers worldwide are feverishly investigating precisely how the illness develops. A team of scientists under the guidance of the University of Bonn and University of Massachusetts (USA) and with the participation of the German Center for Neurodegenerative Diseases have discovered a new signaling pathway in mice which is involved in the development of chronic inflammation which causes nerve cells in the brain to malfunction and die off. The results ...
Multi-tasking whales sing while feeding, not just breeding
2012-12-20
DURHAM, NC -- Humpback whales are famed for their songs, most often heard in breeding season when males are competing to mate with females. In recent years, however, reports of whale songs occurring outside traditional breeding grounds have become more common. A new study may help explain why.
Humpbacks sing for their supper -- or at least, they sing while they hunt for it.
The research, published December 19 in PLoS ONE, uncovers the whales' little-understood acoustic behavior while foraging.
It also reveals a previously unknown behavioral flexibility on their ...
Scientists construct first map of how the brain organizes everything we see
2012-12-20
Our eyes may be our window to the world, but how do we make sense of the thousands of images that flood our retinas each day? Scientists at the University of California, Berkeley, have found that the brain is wired to put in order all the categories of objects and actions that we see. They have created the first interactive map of how the brain organizes these groupings.
The result – achieved through computational models of brain imaging data collected while the subjects watched hours of movie clips – is what researchers call "a continuous semantic space."
Some relationships ...
Are bacteria making you hungry?
2012-12-20
Over the last half decade, it has become increasingly clear that the normal gastrointestinal (GI) bacteria play a variety of very important roles in the biology of human and animals. Now Vic Norris of the University of Rouen, France, and coauthors propose yet another role for GI bacteria: that they exert some control over their hosts' appetites. Their review was published online ahead of print in the Journal of Bacteriology.
This hypothesis is based in large part on observations of the number of roles bacteria are already known to play in host biology, as well as their ...
Policy report calls for raise in minimum wage
2012-12-20
AUSTIN, Texas — Raising the minimum wage to a living wage begins the cycle of lifting single mothers out of poverty, according to a policy report released by the Institute for Urban Policy Research & Analysis (IUPRA) at The University of Texas at Austin.
The U.S. census shows more Americans — 46.2 million people — are living in poverty than ever before. And for African American and Hispanic women, a full-time minimum wage job isn't enough to break out of the poverty cycle. According to the report, working women of color make $0.64 and $0.56, respectively, for every dollar ...